DefinitionThis section has been translated automatically.
Argatroban, a synthetic hirudin analogue (L-arginine derivative), is a direct thrombin inhibitor that reversibly binds to thrombin. The anticoagulant has been approved since 2005 for anticoagulation in adult patients with heparin-induced thrombocytopenia type II (HIT II) who require parenteral antithrombotic therapy
Half-lifeThis section has been translated automatically.
You might also be interested in
Pharmacodynamics (Effect)This section has been translated automatically.
The anticoagulation effect of argatroban is independent of antithrombin III, inhibiting the formation of fibrin, activation of coagulation factors V, VIII and XIII, activation of protein C and activation of platelet aggregation. Argatroban is bound to 54% of human serum proteins. Argatroban is able to inhibit the action of both freely circulating and fibrin-bound thrombin. It does not interact with heparin-induced antibodies. Argatroban is mainly excreted via the feces, probably via biliary secretion.
IndicationThis section has been translated automatically.
Anticoagulation in adult patients with heparin-induced thrombocytopenia type II (HIT-II) who require parenteral antithrombotic therapy The diagnosis should be confirmed by the HIPAA ("heparin induced platelet activation assay") or an appropriate test (Rice L 2005).
Individual reports show positive effects in rhematoid vasculitis (Kawakami T et al. 2008) and zoster-induced pain (Fujii K et al. 2001).
Pregnancy/nursing periodThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Undesirable effectsThis section has been translated automatically.
Frequently: vascular diseases (e.g. bleeding), nausea, skin diseases (e.g. purpura).
Occasionally: heart diseases (e.g. tachycardia, hypertension), liver and bile diseases, skeletal muscle and bone diseases, connective tissue diseases, urinary tract and kidney diseases, general complaints (e.g. pyrexia), diseases of the gastrointestinal tract, diseases of the respiratory tract, chest and mediastinum, skin diseases (e.g. urticaria, alopecia).
InteractionsThis section has been translated automatically.
ContraindicationThis section has been translated automatically.
PreparationsThis section has been translated automatically.
Note(s)This section has been translated automatically.
Treatment with Argatroban should be carried out under the supervision of a doctor experienced in treating coagulation disorders, preferably in an intensive care unit. It should be carried out under close monitoring of the activated partial thromboplastin time (aPTT) until the aPTT is within the target range. Thereafter, monitoring of the aPTT should be performed once a day. The argatrobank concentrations in plasma correlate with the anticoagulation effect measured by the aPTT value.
There is no specific antidote against Argatroban.
LiteratureThis section has been translated automatically.
- Fujii K et al (2001) A specific thrombin inhibitor, argatroban, alleviates herpes zoster-associated pain. J Dermatol 28:200-207.
- Greinacher T (2008) Thrombocytopenia and platelet dysfunction. In: Thomas L (Ed) Laboratory and diagnosis. Th-Books Publishing Company Ltd, Frankfurt/Main p. 918
- Gupta S et al (2008) Heparin induced thrombocytopenia. J Assoc Physicians India 56:622-627.
- Kawakami T et al (2008) Therapeutic effect of argatroban on rheumatoid vasculitis with antiphosphatidylserine-prothrombin complex antibody. Arch Dermatol 144:1075-1076.
- Lewis BE et al (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163: 1849-1856
Rice L (2005) Evolving management strategies for heparin-induced thrombocytopenia. Semin Hematol 42 (3 Suppl 3):15-S21